drugset / Trial / NCT03072147
Teriparatide as a Chondroregenerative Therapy in OA
Phase 2
Completed
76 enrolled
Christopher Ritchlin
Duke University · collabEli Lilly and Company · collabMilton S. Hershey Medical Center · collabUniversity of Rochester · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate teriparatide (TP) as a chondroregenerative therapy for human knee osteoarthritis (OA). The central hypothesis to be tested is that TP supports structural modification of the joint and improves biomarker, functional and patient-reported measures of knee OA.
Timeline
- Start
- 2017-05-01
- Primary completion
- 2022-09-30
- Completion
- 2022-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Teriparatide | Protein / enzyme biologic | 20 ug | Subcutaneous |